English
Back
Open Account
Around 80% of IPOs are expected to rise on their debut in 2026! Xiantong Pharmaceutical is set to li
牛牛新股君
joined discussion · ·

IPO News | Radiopharmaceutical manufacturer Xiantong Medicine launches IPO, plans to list on November 24; one lot subscription amount is HKD 3,434.29

Futu News, November 16:$SINOTAUPHARMA-B (09941.HK)$Announced that the IPO will take place from November 16 to November 19. The company plans a global offering of approximately 6.561 million shares and expects to list on November 24.
Futu News, November 16:$SINOTAUPHARMA-B (09941.HK)$Announced that the IPO will take place from November 16 to November 19. The company plans a global offering of approximately 6.561 million shares and expects to list on November 24. Company Overview The company is dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals with significant market potential. According to a Frost & Sullivan report, the company is the first in China to: (i) obtain marketing approval for an innovative radiopharmaceutical; (ii) obtain a manufacturing license for an innovative radiopharmaceutical as a Marketing Authorization Holder (MAH); and (iii) complete registration clinical trials for therapeutic radioligands and have its New Drug Application (NDA) accepted by the National Medical Products Administration (NMPA). With a foothold in China and a global perspective, the company has established end-to-end capabilities ranging from radionuclide development and production to radiopharmaceutical R&D, manufacturing, and commercialization. According to a Frost & Sullivan report, the company is among the first batch of radiopharmaceutical enterprises in China to achieve full industry chain integration, and one of the few globally to do so. We believe this will build a strong competitive advantage and lay a solid foundation for the company to seize the significant growth opportunities in the radiopharmaceutical industry, which features high technical and regulatory entry barriers. Financial Overview For the years ending December 31, 2024 and 2025, and for the six months ending June 30, 2025 and 2026...
Symbols
--
--
--
Company Overview
The company is dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals with significant market potential. According to a Frost & Sullivan report, the company is the first in China to: (i) obtain marketing approval for an innovative radiopharmaceutical; (ii) obtain a manufacturing license for an innovative radiopharmaceutical as a Marketing Authorization Holder (MAH); and (iii) complete registration clinical trials for therapeutic radioligands and have its New Drug Application (NDA) accepted by the National Medical Products Administration (NMPA).
With a foothold in China and a global perspective, the company has established end-to-end capabilities ranging from radionuclide development and production to radiopharmaceutical R&D, manufacturing, and commercialization. According to a Frost & Sullivan report, the company is among the first batch of radiopharmaceutical enterprises in China to achieve full industry chain integration, and one of the few globally to do so. We believe this will build a strong competitive advantage and lay a solid foundation for the company to seize the significant growth opportunities in the radiopharmaceutical industry, which features high technical and regulatory entry barriers.
Financial Overview
For the years ended December 31, 2024 and 2025, and for the six months ended June 30, 2025 and 2026, the Company recorded revenues of RMB 44.1 million, RMB 99.2 million, RMB 36.9 million, and RMB 61.3 million, respectively. The Company recorded gross profits of RMB 3.4 million and RMB 15.0 million in 2024 and 2025, respectively, with gross profit margins of 7.7% and 15.1% for the same periods.
Futu News, November 16:$SINOTAUPHARMA-B (09941.HK)$Announced that the IPO will take place from November 16 to November 19. The company plans a global offering of approximately 6.561 million shares and expects to list on November 24. Company Overview The company is dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals with significant market potential. According to a Frost & Sullivan report, the company is the first in China to: (i) obtain marketing approval for an innovative radiopharmaceutical; (ii) obtain a manufacturing license for an innovative radiopharmaceutical as a Marketing Authorization Holder (MAH); and (iii) complete registration clinical trials for therapeutic radioligands and have its New Drug Application (NDA) accepted by the National Medical Products Administration (NMPA). With a foothold in China and a global perspective, the company has established end-to-end capabilities ranging from radionuclide development and production to radiopharmaceutical R&D, manufacturing, and commercialization. According to a Frost & Sullivan report, the company is among the first batch of radiopharmaceutical enterprises in China to achieve full industry chain integration, and one of the few globally to do so. We believe this will build a strong competitive advantage and lay a solid foundation for the company to seize the significant growth opportunities in the radiopharmaceutical industry, which features high technical and regulatory entry barriers. Financial Overview For the years ending December 31, 2024 and 2025, and for the six months ending June 30, 2025 and 2026...
Use of Proceeds
Regarding the use of proceeds, Xiantong Medicine expects the net proceeds from the global offering to be approximately HK$329 million (assuming the over-allotment option is not exercised and based on the mid-point of the offer price range of HK$60). According to the prospectus, Xiantong Medicine intends to use the funds raised from the global offering for the following purposes:
88.0% will be used for the R&D and regulatory filing of core products; 4.9% will be used for the R&D of other candidate products; 1.1% will be used to strengthen the Company’s sales and marketing capabilities, including recruiting sales and marketing personnel with extensive knowledge and experience in the field of radiopharmaceuticals, and conducting diversified marketing activities to enhance market awareness of the Company’s products; 1.1% will be used to construct a new production base in Tianjin; and 5.0% will be used for working capital and other general corporate purposes.
The golden season for IPO subscriptions is here! Subscribe to IPOs with Futu: 0% interest, 0 fees, and cash-free subscription. Participate in the campaign now for a chance to waive IPO subscription fees for one year.Try it out now >>
Futu News, November 16:$SINOTAUPHARMA-B (09941.HK)$Announced that the IPO will take place from November 16 to November 19. The company plans a global offering of approximately 6.561 million shares and expects to list on November 24. Company Overview The company is dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals with significant market potential. According to a Frost & Sullivan report, the company is the first in China to: (i) obtain marketing approval for an innovative radiopharmaceutical; (ii) obtain a manufacturing license for an innovative radiopharmaceutical as a Marketing Authorization Holder (MAH); and (iii) complete registration clinical trials for therapeutic radioligands and have its New Drug Application (NDA) accepted by the National Medical Products Administration (NMPA). With a foothold in China and a global perspective, the company has established end-to-end capabilities ranging from radionuclide development and production to radiopharmaceutical R&D, manufacturing, and commercialization. According to a Frost & Sullivan report, the company is among the first batch of radiopharmaceutical enterprises in China to achieve full industry chain integration, and one of the few globally to do so. We believe this will build a strong competitive advantage and lay a solid foundation for the company to seize the significant growth opportunities in the radiopharmaceutical industry, which features high technical and regulatory entry barriers. Financial Overview For the years ending December 31, 2024 and 2025, and for the six months ending June 30, 2025 and 2026...
Editor/Vincent
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
13
35K Views
Report
Comments (3)
Write a Comment...
3
13
13